Drug Profile
Etranacogene dezaparvovec - CSL Behring
Alternative Names: AAV5-FIX-Padua; AAV5-hFIXco-Padua; AMT 061; CSL-222; Etranacogene dezaparvovec - CSL Behring/uniQure; Etranacogene dezaparvovec-drlb; EtranaDez; HEMGENIX; Lanacogene vosiparvovecLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator uniQure
- Developer CSL Behring
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor IX replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilia B
Most Recent Events
- 15 Mar 2024 Registered for Haemophilia B in Australia (IV)
- 28 Feb 2024 UniQure owns a patent family, including patents and patent applications, directed to the use of the Padua mutation in human Factor IX (“hFIX”) for gene therapy in etranacogene dezaparvovec
- 15 Jan 2024 Registered for Haemophilia B in Switzerland (IV)